Skip to content
OpenCapital
Get started
Income StatementBalance SheetCash FlowSegments
Incyte logo

Incyte Balance Sheet Statement

Assets, liabilities, and shareholders' equity

Incyte holds $7.3B in total assets. Shareholders' equity is $5.6B against $39.4M in total debt. Cash and equivalents total $3.5B. The current ratio is 3.68 and debt-to-equity is 0.007. Based on the Q1 2026 filing.

Total Assets$7.3BTotal Stockholders Equity$5.6BCash And Equivalents$3.5BTotal Current Assets$5.5BTotal Current Liabilities$1.5B
Latest FilingQ1 2026
Report Date2026-04-28
Market Cap$21.5B
P/E Ratio15.05
ROE30.82%

Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts payable$197.5M$195.5M$241.1M$171.9M$209.9M$228.6M
Accrued expenses$188.7M$102.8M$129.1M$168.3M$228.1M$124.9M
Accrued Manufacturing Costs$188.7M$102.8M$129.1M$168.3M$228.1M$124.9M
Accrued Marketing and Advertising Expenses$33.4M$53.8M$51.3M$48.9M$71.2M$64.8M
Accrued Royalties (Current)$519.9M$549.2M$33.1M$36.9M$40.7M$37.5M
Other Commercial Liabilities$1.2B$1.4B$857.1M$948.4M$1B$1.1B
Accrued Income Taxes, Current$23.8M$91.7M$5.4M$5.5M$4.8M$5.9M
Accrued Liabilities, Current$1.2B$1.4B$857.1M$948.4M$1B$1.1B
Compensation and benefits$188.7M$102.8M$129.1M$168.3M$228.1M$124.9M
Other accrued liabilities$58.9M$74.5M$72.9M$93.6M$90.7M$78.4M
Current portion of long-term debt$4.4M$4.5M$4.5M$4.5M$4.5M$4.4M
Finance Lease Liability, Current$4.4M$4.5M$4.5M$4.5M$4.5M$4.4M
Income taxes payable$23.8M$91.7M$5.4M$5.5M$4.8M$5.9M
Operating lease liabilities, current$5.6M$6M$6.2M$5.9M$5.7M$5.6M
Total current liabilities$1.6B$1.7B$1.3B$1.3B$1.5B$1.5B

Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts receivable, net$853.2M$823.1M$842.9M$895.9M$1B$1.1B
Available-for-Sale Debt Securities$470.3M$466.9M$466.8M$474.8M$482.8M$554.7M
Cash and cash equivalents$1.7B$1.9B$2B$2.5B$3.1B$3.5B
Debt securities - current$470.3M$466.9M$466.8M$474.8M$482.8M$554.7M
Finished goods$48.4M$47.5M$56.8M$64.9M$71.8M$58.9M
Trading assets—$256.9M$221.4M$177.8M—$217.1M
Finished goods$48.4M$47.5M$56.8M$64.9M$71.8M$58.9M
Raw materials$27.6M$29.9M$33M$30.7M$27.9M$36.6M
Work in process$331.2M$351.9M$361.7M$354.4M$343.7M$351.6M
Inventories$348.3M$365.3M$368.1M$366.5M$342.2M$331.4M
Prepaid expenses and other current assets$168.9M$211.7M$295.6M$368.7M$317.8M$301.3M
Restricted cash$1.6M$1.7M$1.8M$1.8M$1.9M$1.8M
Total current assets$3.2B$3.5B$3.6B$4.3B$5B$5.5B

Equity

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Additional paid-in capital$4.5B$4.6B$4.7B$4.7B$4.9B$5.1B
Accumulated other comprehensive income (loss)-$13.1M-$6.2M$13.4M$14.6M$25.5M$22.3M
Common stock193K400M400M400M400M400M
Common Stock Par Value Per Share$0.00$0.00$0.00$0.00$0.00$0.00
Common Stock Shares Issued193.4M193.8M194.1M196.1M198.5M199.9M
Convertible Preferred Stock Authorized Shares5M5M5M5M5M5M
Convertible Preferred Stock Issued Shares000000
Convertible Preferred Stock Outstanding Shares000000
Additional paid-in capital$4.5B$4.6B$4.7B$4.7B$4.9B$5.1B
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively$193K$193K$194K$196K$198K$200K
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding$0$0$0$0$0$0
Preferred stock$0$0$0$0$0$0
Preferred Stock Par Value Per Share$0.00$0.00$0.00$0.00$0.00$0.00
Retained earnings-$1.1B-$914.7M-$509.7M-$85.5M$213.8M$517.1M
Share-Based Payment Award Options Outstanding - Number8.7M8.5M8.5M9.9M9.3M9.1M
Share-Based Payment - Unrecognized Cost of Nonvested Awards$67.81$67.18$67.67$66.59$66.86$67.85
Shares Reserved for Future Issuance Under Stock Plans4M3.2M11.8M8.9M9.1M8.8M
Total liabilities and stockholders' equity$5.4B$5.7B$5.8B$6.3B$7B$7.3B
Total stockholders' equity$3.4B$3.7B$4.2B$4.7B$5.2B$5.6B

Non-Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Allowance for credit losses$0$0$0$0$0$0
Deferred Tax Assets and Other Non-Current Assets$10.8M$30.2M$32.6M$32.3M$18.2M$24.5M
Equity Securities (FV-NI) - Non-Current$18.8M$17.5M$13.3M$21.9M$48M$54.6M
Equity Securities (Non-Current)$18.8M$17.5M$13.3M$21.9M$48M$54.6M
Available-for-sale securities—$210M$245.4M$297.1M—$337.7M
Total investments$18.8M$17.5M$13.3M$21.9M$48M$54.6M
Goodwill$155.6M$155.6M$155.6M$155.6M$133M$133M
Intangible assets, net$113.8M$107.6M$126.4M$119.4M$117.1M$110.2M
Deferred tax assets$762.1M$768.9M$652.3M$528.1M$515.3M$452.5M
Other non-current assets$10.8M$30.2M$32.6M$32.3M$18.2M$24.5M
Other Intangible Assets Net$113.8M$107.6M$126.4M$119.4M$117.1M$110.2M
Property, plant and equipment at cost$1.1B$1.1B$1.1B$1.2B$1.1B$1.1B
Operating lease right-of-use assets$30.8M$29.9M$29M$28.2M$27.5M$26.7M
Other non-current assets$10.8M$30.2M$32.6M$32.3M$18.2M$24.5M
Accumulated depreciation$328M$343.6M$346.4M$360.6M$375.1M$389M
Property and equipment, net$763.4M$765.4M$798.5M$798.6M$730.9M$720.2M
Software and Technology Licenses, Net$10.8M$30.2M$32.6M$32.3M$18.2M$24.5M
Total assets$5.4B$5.7B$5.8B$6.3B$7B$7.3B

Non-Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Contingent Consideration Liability (Non-Current)$153.8M$153.3M$160.2M$138.4M$79.9M$70.6M
Finance lease liabilities$33.5M$32.6M$31.8M$30.9M$30.2M$29.4M
Marketing and selling$33.4M$53.8M$51.3M$48.9M$71.2M$64.8M
Other non-current liabilities$167.5M$175.6M$179.9M$171.2M$165.3M$126.6M
Total liabilities$2B$2.1B$1.7B$1.7B$1.8B$1.7B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Cumulative Cost Basis$1.1B$1.1B$1.1B$1.2B$1.1B$1.1B
Expected Pension Contributions—$10.1M$10.1M$10.1M—$12.6M
Accounts Receivable, after Allowance for Credit Loss$853.2M$823.1M$842.9M$895.9M$1B$1.1B
Clinical related costs$132.4M$132.7M$146.3M$157.7M$175.9M$177.7M
Licensing Arrangements$519.9M$549.2M$33.1M$36.9M$40.7M$37.5M
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five—$210M$245.4M$297.1M—$337.7M
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One—$256.9M$221.4M$177.8M—$217.1M
Common stock, par value (in dollars per share)$0$0$0$0$0$0
Common stock, shares authorized (in shares)$400M$400M$400M$400M$400M$400M
Common stock, shares issued (in shares)$193.4M$193.8M$194.1M$196.1M$198.5M$199.9M
Common Stock, Shares, Outstanding$193.4M$193.8M$194.1M$196.1M$198.5M$199.9M
Debt Securities, Available-for-Sale, Allowance for Credit Loss$0$0$0$0$0$0
Investments$469.9M$465.7M$465.5M$473.1M$480.8M$555.2M
Estimated Fair Value—$466.9M$466.8M$474.8M—$554.7M
Defined Benefit Plan Expected Future Employer Contributions Current Fiscal Year—$10.1M$10.1M$10.1M—$12.6M
Current maturities of long-term debt$4.4M$4.5M$4.5M$4.5M$4.5M$4.4M
Finance Lease, Right-of-Use Asset, after Accumulated Amortization$30.8M$29.9M$29M$28.2M$27.5M$26.7M
Inventory Net Current and Noncurrent$407.2M$429.3M$451.5M$450M$443.3M$447M
Inventory incurred prior to FDA approval—$27.7M$47.4M$45.4M—$40.9M
Preferred Stock, Par or Stated Value Per Share$0$0$0$0$0$0
Preferred Stock, Shares Authorized$5M$5M$5M$5M$5M$5M
Preferred Stock, Shares Issued$0$0$0$0$0$0
Preferred Stock, Shares Outstanding$0$0$0$0$0$0
Provision for contract loss$438.1M$467.8M$542M$599.9M$642.5M$722.4M
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value$67.8$67.2$67.7$66.6$66.9$67.9
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number$8.7M$8.5M$8.5M$9.9M$9.3M$9.1M
Incentive stock program, shares reserved for future grants (in shares)$4M$3.2M$11.8M$8.9M$9.1M$8.8M